002734 Limin Group
- 7.56
- +0.09+1.20%
Limin Group News
limin group (002734.SZ) distributed 1.5 yuan per 10 shares for the semi-annual period, with a record date of October 17th.
limin group (002734.SZ) announced that the company will implement the interim equity distribution for the first half of 2024, with a distribution of 10...
limin group (002734.SZ): The products exported to Southeast Asia are mainly self-exported, and some are sold through foreign trade companies.
Gelonghui October 11th | limin group (002734.SZ) stated on the investor interactive platform that the company's products exported to Southeast Asia are primarily self-exported, some are sold through foreign trade companies. The company's products such as dendrobium manganese zinc, benzoic acid etherazole, and pyraclostrobin are used as mainstream fungicides in the Southeast Asian market, with relevant certificates for local independent registration and authorized registration. The Southeast Asian market has a high acceptance of patented new agricultural pesticide products, and the registration policies are similar to those in China, making it an important overseas target market for the company's future layout.
Limin Group Expects Up to 141% Profit Jump in January-September Period
Limin Co., Ltd.: The company\'s performance forecast for the first three quarters of 2024
Limin Group (002734.SZ) announced a forecasted increase, with an expected net income of 49 million yuan to 53 million yuan for the first three quarters, an increase of 122.76% to 140.95%.
Limin Group (002734.SZ) released a performance forecast for the first three quarters of 2024, expecting the attributable profits to the listed...
Limin Group (002734.SZ): signed a strategic cooperation agreement with Zhi Sheng You Gu.
Limin Group (002734.SZ) announced on September 25th, 2024, Limin Holding Group Co., Ltd. and Shanghai Zhisheng Yougu Biotechnology Co., Ltd. (hereinafter referred to as "Zhisheng Yougu") signed a "Global Strategy Cooperation Agreement" based on their respective global strategy layouts and business advantages, jointly dedicated to synthetic biotechnology, jointly creating and developing, and promoting the application of new RNA biological pesticides. Further enhance the company's core competitiveness and sustainable development capabilities, and contribute to the safe, green, and healthy development of agriculture. Both parties jointly create and develop targeted and environmentally friendly products.
Limin's Unit Gets Nod to Set Up Multifunctional Plant in China's Xuzhou City
Limin Group (002734.SZ): Subsidiary obtains investment project filing certificate
On September 18th, Gelonghui announced that Limin Group (002734.SZ) recently announced that its wholly-owned subsidiary, Limin Chemical Co., Ltd. (hereinafter referred to as Limin Chemical), has obtained the "Jiangsu Province Investment Project Filing Certificate" issued by the Xuzhou Industrial and Information Bureau [Filing Certificate No.: Xuzhou Industrial and Information Backup (2024) No. 3], The specific details are as follows: 1. Project name: Annual production of 100 tons of new efficient multifunctional pesticide raw material technology improvement project. 2. Filing approval institution: Xuzhou Industrial and Information Bureau. 3. Project overview: In order to further enhance the company's core competitiveness, it plans to invest in the construction of this project. The project plans to invest 50 million.
limin group (002734.SZ): Currently, the company's API production capacity is 0.1027 million tons, and the formulation production capacity is 0.1144 million tons.
Limin Group (002734.SZ) stated on the investor interaction platform on September 11 that the company has the advantage of a complete industry chain in the field of biologically fermentation, semi-synthetic biology, and formulation processing. It has advanced biologically fermentation technology, chemical synthesis technology, and formulation compatibility technology, which gives it advantages in terms of product cost, quality, and supply. Currently, the company's capacity for raw materials is 0.1027 million tons, and the capacity for formulation is 0.1144 million tons. The capacity utilization rate in 2023 is 68.35% for raw materials and 85.28% for formulations. In the first half of this year, the production of raw materials increased by 16.59% year-on-year, and the production of formulations increased by 19%.
limin group (002734.SZ): Currently, the company's products such as avemycin and methionine are in short supply.
Gelonghui September 11th, limin group (002734.SZ) stated on the investor interaction platform that currently the company's products such as avilamycin and methionine salt are in short supply, and prices continue to rebound. The company's production is being appropriately adjusted based on sales orders.
Limin GroupLtd's (SZSE:002734) Anemic Earnings Might Be Worse Than You Think
Limin Group (002734.SZ) has repurchased 3.8308% of its shares, with an approximate cost of 0.1 billion yuan.
Limin Group (002734.SZ) announced that, as of August 31, 2024, the company has repurchased special...
Limin shares: 2024 semi-annual report
Limin shares: summary of the 2024 semi-annual report
Limin Group (002734.SZ): The net income in the first half of the year was 31.7362 million yuan, a year-on-year decrease of 44.84%.
Limin Group (002734.SZ) announced its semi-annual report for 2024, with total operating income of 2.298 billion yuan, a decrease of 0.34% compared to the same period last year; net income attributable to shareholders of the listed company was 31.7362 million yuan, a decrease of 44.84% compared to the same period last year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 28.3788 million yuan, a decrease of 46.68% compared to the same period last year; basic earnings per share were 0.09 yuan.
Limin Group (002734.SZ) released its performance for the first half of the year, with a net income of 31.7362 million yuan, a decrease of 44.84%.
Limin Group (002734.SZ) released the 2024 interim report. During the reporting period, the company achieved revenue...
Limin Group (002734.SZ): has already repurchased 3.8308% of the shares.
Limin Group (002734.SZ) announced on August 5th that as of July 31, 2024, the company had accumulated a buyback of 14,053,700 shares through a buyback special securities account via centralized bidding trading method, accounting for approximately 3.8308% of the company's total share capital. The highest fill price was 8.15 yuan/share, and the lowest fill price was 6.09 yuan/share. The total trade amount was 100,001,505.53 yuan (excluding transaction fees). This buyback is in line with the company's buyback plan.
Limin Group (002734.SZ): Will focus on the "biosynthesis" product direction.
On July 23, Gelonhui reported that Limin Group (002734.SZ) stated during investor relations activities that it is increasing its investment in technology research and development, and is currently building a synthetic biology (enzyme engineering, genetic engineering) laboratory, with a focus on developing "bio-synthesis" products.
Limin Group (002734.SZ): In Q1, most product prices fell to historic lows, with clear signs of rebound in Q2.
On July 23, Gelonhui reported that the Limin Group (002734.SZ) stated in an investor relations activity that the company currently has three major business types: international, domestic crop protection, and APIs. With the clearance of overseas channel inventory and the arrival of the medication peak season, the sales amount and sales volume of international and API businesses are higher than last year; overall, the capacity utilization rate of the company's equipment has improved year-on-year. Most product prices fell to a historical low in Q1, and there were obvious signs of bottoming out in Q2, such as the price increases and supply shortages of the company's products such as Avilamycin, Methomyl, Thiamethoxam, Fipronil, and Thiazuron. Recently, Pien Tze Huang was priced at 165.
Limin Group (002734.SZ): Currently industrialized products include avilamycin, ammonium glyphosate, polyoxin, and prohexadione calcium.
Limin Group (002734.SZ) stated on the investor interaction platform on July 16 that synthetic biology, as a cutting-edge interdisciplinary subject, is gradually becoming an important force to promote technological innovation and industrial development, and is regarded as a key component of new productive forces. The development of new biological pesticides using enzymatic methods instead of traditional chemical processes has significant advantages in synthesis. According to the 2021-2025 strategic development plan, the company focuses on the "bio-manufacturing" product direction based on its own resource advantages and industry policy guidance, mainly including bio-fermentation engineering products and bio-semi-synthetic products.
Analysis
Price Target
No Data
No Data